Today: 20 March 2026
Subscribe
Browse Category

Pfizer 1 November 2025 - 19 December 2025

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer Stock After Hours Today (Dec. 18, 2025): PFE Holds Near $25 — What to Know Before Friday’s Market Open

Pfizer shares closed Thursday at $25.04 and held near that level in after-hours trading as investors weighed the company’s 2026 outlook and ongoing U.S. drug pricing policy changes. Pfizer forecast 2026 revenue between $59.5 billion and $62.5 billion, and adjusted EPS of $2.80 to $3.00. The company expects COVID-19 product sales to drop to about $5 billion in 2026.
19 December 2025
··
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer shares fell nearly 5% to about $25 in U.S. trading Tuesday after the company issued 2026 guidance with adjusted EPS of $2.80–$3.00, below Wall Street estimates. The stock reversed early gains as investors reacted to lower COVID-19 sales and patent expirations expected to pressure results next year. Trading volume topped 55 million shares by late morning.
16 December 2025
····
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer shares closed Monday at $26.43, up 2.24%, then slipped to $26.34 after hours. Investors are awaiting Tuesday’s analyst call, where management is set to outline 2026 guidance. The company announced a new autoimmune research deal with Adaptive Biotechnologies, worth up to $890 million in milestones. Trading volume was about 60 million shares, below average.
16 December 2025
···
Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer Stock (PFE) News, Forecasts, and Analyst Outlook: What’s Driving Shares on December 15, 2025

Pfizer shares traded near $26.36 on December 15, 2025, close to their 52-week high, with a market cap around $150 billion. The company announced new immunology research agreements with Adaptive Biotechnologies worth up to $890 million. Investors are awaiting Pfizer’s full-year 2026 guidance call scheduled for December 16. Dividend yield stands at about 6.5%, with analyst consensus broadly Hold.
15 December 2025
··
Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer Stock (PFE) News Today: Dividend, 2026 Guidance Call, Obesity Deals, and Analyst Forecasts (Dec. 15, 2025)

Pfizer shares traded at $25.85 as of 12:08 UTC Monday, unchanged from Friday’s close. The company will hold a conference call Tuesday morning to provide full-year 2026 financial guidance. Pfizer’s board declared a $0.43 first-quarter 2026 dividend, marking its 349th consecutive quarterly payout. Market cap stands near $147 billion.
15 December 2025
····
Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer Stock (PFE) Outlook: This Week’s Key Headlines, Dividend Update, and What to Watch Ahead of 2026 Guidance (Updated Dec. 14, 2025)

Pfizer shares closed at $25.85, below their 52-week high but above the low. The company declared a $0.43 first-quarter 2026 dividend, its 349th consecutive payout. Investors await Tuesday’s analyst call, where management will issue full-year 2026 guidance. A new obesity drug licensing deal with YaoPharma was also announced.
14 December 2025
··
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer shares closed down 1.7% at $25.33 on December 9, 2025, with volume below average. After hours, the stock edged up to $25.40 as investors reacted to Pfizer’s new global licensing deal with YaoPharma for an early-stage oral obesity drug. The agreement includes a $150 million upfront payment and potential milestones up to $2.1 billion.
10 December 2025
····
Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer (PFE) Stock on November 30, 2025: Institutional Buying, Metsera Deal and a 6.7% Dividend Yield

Pfizer shares closed at $25.74 on November 28, 2025, down 1.8% over the past year. Regulatory filings show new institutional buying, and the company completed a Metsera acquisition worth up to $10 billion. Pfizer reduced its BioNTech stake by 54.7% and raised its full-year EPS guidance to $3.00–$3.15 after reporting $16.7 billion in Q3 revenue.
30 November 2025
····
Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer shares rose 2.62% to close at $25.04 Friday after the FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer and positive data emerged for its mRNA flu vaccine. Volume reached 73 million shares. The stock outperformed Johnson & Johnson and Eli Lilly but remains about 10% below its 52-week high. Pfizer is still down for the year and trades well below pandemic-era peaks.
22 November 2025
··
Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer Stock Surges on Trump’s Drug Price Deal & $7B Obesity Gamble – Is This the Comeback Investors Hoped For?

Pfizer shares surged 15% in late September after announcing a Medicaid drug price deal with the Trump administration, but fell back to $24.65 by Oct. 31. The company will report Q3 2025 earnings on Nov. 4, with analysts expecting a year-over-year drop in profit. Pfizer agreed to buy obesity drug developer Metsera for up to $7.3 billion as it seeks new growth beyond COVID-19 products.
1 November 2025
··
1 2

Stock Market Today

  • Kuwait Refinery Hit Amid Iran-Israel Conflict Affecting Gulf Energy Supplies
    March 20, 2026, 8:05 AM EDT. A fire at Kuwait's Mina Al-Ahmadi oil refinery followed another drone strike linked to Iran, intensifying concerns over Gulf energy infrastructure amid regional conflict. The incident occurred a day after Qatar's Ras Laffan facility was targeted. Iran pledged retaliation following an Israeli strike damaging its South Pars gas field, a key energy source. Israeli Prime Minister Benjamin Netanyahu claimed victory against Iran, signaling the conflict's potential end but hinted at a possible ground offensive. Iranian officials maintained missile production despite ongoing bombardments. The war dampened New Year celebrations across Iran and the Gulf, with Tehran still facing Israeli bombardments. The escalating attacks threaten significant disruption to oil and gas supplies flowing through the strategic Strait of Hormuz, crucial for global energy markets.
Go toTop